C34 (CAS 40592-88-9) TLR4 Inhibitor: Selective Modulation of Inflammatory Signaling

Executive Summary: C34 is a synthetic, 2-acetamidopyranoside TLR4 inhibitor with high selectivity, sparing TLR2 and TLR9 pathways (APExBIO product information). At 10 μM in vitro, it significantly suppresses TLR4 signaling in macrophages and enterocytes. In vivo, C34 at 1 mg/kg reduces systemic inflammation and TNFα expression in models of endotoxemia and necrotizing enterocolitis (DOI:10.1016/j.jep.2024.118943). Its purity (98%) and QC documentation enable reproducible results. C34 serves as a benchmark TLR4 inhibitor for dissecting Toll-like receptor signaling in inflammatory disease research.

Biological Rationale

Toll-like receptor 4 (TLR4) is a pattern recognition receptor central to innate immunity and inflammation. Activation of TLR4 by lipopolysaccharide (LPS) or endogenous danger signals leads to NF-κB and NLRP3 inflammasome activation, driving production of pro-inflammatory cytokines such as TNFα and IL-1β (DOI:10.1016/j.jep.2024.118943). Dysregulated TLR4 signaling is implicated in sepsis, necrotizing enterocolitis, and age-associated neuroinflammation (see related research). Selective inhibition of TLR4 enables mechanistic dissection of its role in macrophages, enterocytes, and microglia, while minimizing off-target effects common to broader anti-inflammatory agents.

Mechanism of Action of C34 (CAS 40592-88-9) TLR4 Inhibitor

C34 is a small molecule structurally defined as (2R,3S,4R,5R,6S)-5-acetamido-2-(acetoxymethyl)-6-isopropoxytetrahydro-2H-pyran-3,4-diyl diacetate (product specification). It blocks TLR4-mediated signal transduction, inhibiting downstream activation of the NF-κB and NLRP3 pathways in immune cells. C34 does not directly affect TLR2 or TLR9, ensuring pathway selectivity. In vitro, C34 suppresses LPS-induced TNFα and iNOS expression in both human and murine models, suggesting action at or upstream of TLR4 receptor engagement. Its crystalline solid form is DMSO-soluble and stable at -20°C for long-term storage, although working solutions should be used promptly to maintain activity.

Evidence & Benchmarks

• C34 at 10 μM in vitro significantly inhibits TLR4 signaling in macrophages and enterocytes, with minimal impact on TLR2/TLR9 (APExBIO).
• In mouse models of endotoxemia, C34 at 1 mg/kg reduces systemic TNFα levels and inflammatory pathology (DOI:10.1016/j.jep.2024.118943).
• C34 down-regulates both basal and LPS-induced TNFα and iNOS in human intestinal explants from necrotizing enterocolitis patients (DOI).
• Compared to natural TLR4 modulators such as Taxus chinensis fruit extract, C34 exhibits equivalent benchmark inhibition of TLR4/NF-κB/NLRP3 signaling in microglia and macrophages (see translational comparison).
• Quality control documentation for C34 includes mass spectrometry, NMR, and MSDS, supporting reproducibility for research use (APExBIO).

This article extends prior summaries of Taxus chinensis fruit TLR4 inhibition by providing a direct comparison to C34’s synthetic, well-validated activity profile, as detailed in "C34 TLR4 Inhibitor: Advancing Translational Inflammatory Research". Where natural extracts demonstrate multi-component effects, C34 offers single-agent selectivity and batch consistency.

For further mechanistic context, see "Taxus chinensis Fruit Extract Suppresses Neuroinflammation via TLR4", which explores plant-derived TLR4 inhibitors in the context of neuroinflammation, contrasting with C34’s direct chemical inhibition and established pharmacodynamics.

Applications, Limits & Misconceptions

C34 is suitable for inflammatory signaling research, particularly where precise TLR4 pathway dissection is required. It is validated for use in models of sepsis, necrotizing enterocolitis, and neuroinflammation. Application in human primary cells and tissue explants is supported, but translation to clinical use has not been established. Researchers should be aware that C34’s effects are limited to TLR4; it will not suppress TLR2/TLR9-driven responses (product details).

C34 does not address all aspects of inflammation, such as those mediated by cytokines independently of TLR4. Natural compound mixtures, like Taxus chinensis fruit extract, may exhibit broader immunomodulatory activity, but with greater batch-to-batch variability and off-target effects (DOI:10.1016/j.jep.2024.118943).

Common Pitfalls or Misconceptions

• C34 is not a pan-TLR inhibitor: It selectively blocks TLR4, with no impact on TLR2 or TLR9.
• Not for clinical use: C34 is intended for research purposes only; there are no clinical efficacy or safety data.
• Activity is concentration-dependent: In vitro efficacy is demonstrated at ~10 μM; sub-micromolar concentrations may be insufficient.
• Solution stability: C34 working solutions in DMSO should be used promptly; long-term solution storage reduces activity.
• Single pathway targeting: Inflammatory responses driven by non-TLR4 pathways will not be affected by C34.

Workflow Integration & Parameters

Researchers can integrate C34 into in vitro and in vivo protocols to interrogate TLR4-dependent inflammatory signaling. Its high purity and stable QC profile from APExBIO facilitate reproducibility. C34 is especially recommended for benchmarking natural inhibitors or dissecting the specific contributions of TLR4 in multi-pathway inflammatory networks.

Protocol Parameters

• In vitro TLR4 inhibition: Use C34 at 10 μM for 1–24 hours exposure in cultured macrophages or enterocytes; dissolve in DMSO, final DMSO concentration ≤0.1% v/v.
• In vivo studies (mouse): Administer C34 at 1 mg/kg by intraperitoneal injection prior to or during LPS/endotoxemia challenge; observe for reduction in systemic TNFα and iNOS expression.
• Storage: Store C34 powder at -20°C; prepare fresh DMSO stock solutions immediately before use.
• QC controls: Validate compound identity and purity by MS and NMR (refer to APExBIO QC documents).

For comparison with natural TLR4 modulators, see related mechanistic research—C34 enables single-pathway dissection, whereas plant extracts may trigger parallel signaling events.

Conclusion & Outlook

C34 (CAS 40592-88-9) is a validated, selective TLR4 inhibitor suitable for cell and animal models of inflammation. It serves as a reproducible benchmark for dissecting TLR4 signaling in macrophages, enterocytes, and microglia. Comparative studies with natural TLR4 modulators (e.g., Taxus chinensis fruit extract) confirm C34’s utility in both basic and translational research (DOI:10.1016/j.jep.2024.118943). While C34 is not a therapeutic, its defined mechanism and QC documentation from APExBIO make it a gold-standard tool compound in inflammatory signaling research. Future studies may further clarify the boundaries of TLR4-specific inhibition in complex disease models, and facilitate rational design of next-generation pathway-selective agents.